US10596246B2 - Adjuvanted combinations of meningococcal factor H binding proteins - Google Patents

Adjuvanted combinations of meningococcal factor H binding proteins Download PDF

Info

Publication number
US10596246B2
US10596246B2 US14/368,957 US201114368957A US10596246B2 US 10596246 B2 US10596246 B2 US 10596246B2 US 201114368957 A US201114368957 A US 201114368957A US 10596246 B2 US10596246 B2 US 10596246B2
Authority
US
United States
Prior art keywords
seq
fhbp
antigen
meningococcal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/368,957
Other languages
English (en)
Other versions
US20150209419A1 (en
Inventor
Beatrice Maria Arico
Brunella Brunelli
Maurizio Comanducci
Mariagrazia Pizza
Silvana Savino
Maria Scarselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
GSK Vaccines SRL
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of US20150209419A1 publication Critical patent/US20150209419A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS SRL reassignment NOVARTIS VACCINES AND DIAGNOSTICS SRL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COMANDUCCI, MAURIZIO, BRUNELLI, BRUNELLA, PIZZA, MARIAGRAZIA, SAVINO, SILVANA, SCARSELLI, MARIA, ARICO, MARIA
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS AG
Application granted granted Critical
Publication of US10596246B2 publication Critical patent/US10596246B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Definitions

  • the invention is in the field of meningococcal vaccines, in particular those containing fHbp.
  • Neisseria meningitidis is a Gram-negative spherical bacterium.
  • Current meningococcal vaccines are also based on capsular saccharides. These include monovalent serogroup C conjugate vaccines and 4-valent conjugate mixtures for serogroups A, C, W135 and Y. There is currently no useful vaccine authorised for general use against serogroup B (‘MenB’).
  • fHbp factor H binding protein
  • the fHbp antigen falls into three distinct variants or families [8] and it has been found that serum raised against a given family is bactericidal within the same family, but is not active against strains which express one of the other two families i.e. there is intra-family cross-protection, but not inter-family cross-protection.
  • reference 8 proposes to combine different variants of fHbp into a single vaccine composition, thereby increasing strain coverage, either as a mixture of separate proteins or as a fusion protein of the different variants (the latter being ‘tandem proteins’).
  • Family I of fHbp includes strain MC58, which is the strain which was used for the first genomic sequence publication [9] and is available from the ATCC as “BAA-335”.
  • the MC58 sequence for fHbp is SEQ ID NO: 1 herein, shown in SEQ ID NO: 26 starting at the cysteine at the N-terminus of the mature meningococcal protein.
  • Family I also includes strain M01573 [5], whose sequence is SEQ ID NO: 23 herein (also referred to as the “B01” or “CDC1573” sequence; see database entry GI:40353481). SEQ ID NOs: 23 and 26 are aligned below.
  • M01573 fHbp sequence is proposed for use in a human vaccine [10], and despite its close sequence relationship to fHbp from strain MC58, the inventors have found that serum raised against the M01573 sequence offers poor protection against the MC58 strain. As MC58 is representative of at least 30% of circulating family I strains, the M01573 sequence thus offers poor coverage of family I. It is an object of the invention to address this poor coverage, and to provide further and improved vaccine compositions which include fHbp antigens from multiple families. In broad terms, this object is achieved in two ways:
  • a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 (SEQ ID NO: 1) than to M01573 (SEQ ID NO: 23), and the other vice versa.
  • the invention provides an immunogenic composition which comprises a first fHbp antigen and a second fHbp antigen, wherein: the first fHbp antigen comprises an amino acid sequence which is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 23; and the second fHbp antigen comprises an amino acid sequence which is more closely related to SEQ ID NO: 23 than to SEQ ID NO: 1.
  • this immunogenic composition can include further antigen components in addition to these two fHbp antigens.
  • a multi-family fHbp-based vaccine uses a family I sequence which is more closely related to MC58 than to M01573, in combination with a family III sequence (e.g. SEQ ID NO: 25 from strain M01240320).
  • the invention provides an immunogenic composition which comprises a first fHbp antigen and a second fHbp antigen, wherein: the first fHbp antigen comprises an amino acid sequence which is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 23; and the second fHbp antigen comprises an amino acid sequence (i) having at least w % sequence identity to SEQ ID NO: 25 and/or (ii) consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 25.
  • the value of w is at least 94 (e.g. 95, 96, 97, 98, 99 or more).
  • the value of x is either (a) at least 50 e.g.
  • the first and second fHbp antigens have different amino acid sequences.
  • this immunogenic composition can include further antigen components in addition to these two fHbp antigens but, preferably, it does not include a fHbp antigen comprising an amino acid sequence with ⁇ 95% identity to SEQ ID NO: 23.
  • Immunogenic compositions of the invention are adjuvanted.
  • the adjuvant comprises an aluminium phosphate salt (see below).
  • compositions of the invention include at least two different meningococcal factor H binding proteins (fHbp) to generate distinct immune responses which are not fully cross-reactive and which provide a broader spectrum of strain coverage against meningococci that the single fHbps alone.
  • fHbp meningococcal factor H binding proteins
  • a composition in the invention's first aspect, includes two family I fHbp antigen sequences. The first of these is more closely related to MC58 than to M01573; the second is more closely related to M01573 than to MC58.
  • a composition includes a fHbp which is more closely related to MC58 than to M01573.
  • a fHbp antigen sequence may be defined as more closely related to MC58 than to M01573 if it meets one or more of the following criteria:
  • a sequence preferably meets at least criterion (b) or (c), more preferably at least (b) & (c), even more preferably at least (a), (b) & (c), and most preferably all six.
  • a fHbp antigen sequence may be defined as more closely related to M01573 than to MC58 if it meets one or more of the following criteria:
  • a sequence preferably meets at least criterion (a) or (c), more preferably at least (a) & (c), even more preferably at least (a), (b) & (c), and most preferably all six.
  • the second fHbp antigen comprises an amino acid sequence (i) having at least w % sequence identity to SEQ ID NO: 25 and/or (ii) consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 25.
  • the value of w is at least 94 (e.g. 95, 96, 97, 98, 99 or more).
  • the value of x is either (a) at least 50 e.g. 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 180, 200 or (b) at least 7 (e.g.
  • fragments comprise an epitope from SEQ ID NO: 25.
  • fHbp sequences which are more closely related to MC58 than to M01573, or vice versa, or which comprise a sequence with ⁇ 94% identity to and/or a fragment of SEQ ID NO: 25, can be designed based on these known sequences, or they can be selected from the large number of wild-type fHbp sequences which have been reported in the art e.g. see references 1-8 and 14-19.
  • Suitable amino acid sequences used with the invention may, compared to SEQ ID NOs: 1 and 23, include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) conservative amino acid replacements i.e. replacements of one amino acid with another which has a related side chain.
  • Genetically-encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e.
  • the antigens may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid deletions relative to a reference sequence.
  • the antigens may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) insertions (e.g. each of 1, 2, 3, 4 or 5 amino acids) relative to a reference sequence.
  • a composition of the invention can include only two different fHbp sequences, or can include more than two different fHbp sequences.
  • a composition of the first aspect may or may not include further fHbp sequences beyond the two fHbp sequences discussed above e.g. it may include a fHbp sequence from family II and/or from family III e.g. SEQ ID NO: 2 and/or SEQ ID NO: 3 herein.
  • a composition may be a bivalent fHbp composition, or may include be more than two different fHbp sequences e.g. in a trivalent or tetravalent fHbp composition.
  • a composition of the first aspect comprises two family I fHbp sequences, and ideally also includes a fHbp sequence from family II and/or family III.
  • it includes a fHbp antigen comprising an amino acid sequence (i) having at least w % sequence identity to SEQ ID NO: 25 and/or (ii) consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 25.
  • the values of w and x are given above, and preferred fragments comprise an epitope from SEQ ID NO: 25.
  • Such fHbp antigens may elicit antibodies in a mouse which are bactericidal against strain 961-5945 in a serum bactericidal assay; for example, providing a serum bactericidal titer of ⁇ 1:4 using the Goldschneider assay with human complement [11-13], and/or providing a serum bactericidal titer of ⁇ 1:128 using baby rabbit complement.
  • Strain 961-5945 has been widely reported in the literature (e.g. see refs. 1, 2 & 20-26) and is available as isolate MDU 9615945, id 1002, from the Neisseria PubMLST collection. It is a B:2b:P1.21,16 strain with electrophoretic type A4 and MLST type 153. Its fHbp sequence is given in reference 23, GI:106073476.
  • composition of the first aspect may comprise (i) first and second fHbp antigens as defined above, and (ii) a third fHbp antigen comprising an amino acid sequence (i) having at least w % sequence identity to SEQ ID NO: 25 and/or (ii) consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 25.
  • a composition of the second aspect comprises two different fHbp antigens as disclosed above.
  • the composition may include a third fHbp antigen, but anyway it is preferred that the composition does not include (i) an antigen comprising an amino acid sequence which has >95% sequence identity to SEQ ID NO: 23 or (ii) an antigen comprising an amino acid sequence which has >95% sequence identity to SEQ ID NO: 24.
  • a fHbp antigen in a composition of the invention may be lipidated e.g. at a N-terminus cysteine. In other embodiments, however, fHbp antigen(s) are not lipidated.
  • lipids attached to cysteines will usually include palmitoyl residues e.g. as tripalmitoyl-S-glyceryl-cysteine (Pam3Cys), dipalmitoyl-S-glyceryl cysteine (Pam2Cys), N-acetyl (dipalmitoyl-S-glyceryl cysteine), etc.
  • Examples of mature lipidated fHbp sequences are SEQ ID NO: 23 (including SEQ ID NO: 4), SEQ ID NO: 24 (including SEQ ID NO: 5), and SEQ ID NO: 25 (including SEQ ID NO: 6).
  • compositions comprise different meningococcal fHbp antigens
  • these may be present as separate polypeptides (e.g. a first and second polypeptide) or they may be present as part of a single ‘hybrid’ polypeptide i.e. where at least two (e.g. 2, 3, 4, 5, or more) fHbp antigens are expressed as a single polypeptide chain (fusion protein), as disclosed for meningococcal antigens in reference 27.
  • Hybrid polypeptides can be represented by the formula NH 2 -A- ⁇ -X-L- ⁇ n -B-COOH, wherein: each X is an amino acid sequence of a different fHbp antigen as defined above; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; n is an integer of 2 or more (e.g. 2, 3, 4, 5, 6, etc.). Usually n is 2 or 3.
  • a -X- moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid protein.
  • the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein i.e. the leader peptide of X 1 will be retained, but the leader peptides of X 2 . . . X n will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X 1 as moiety -A-.
  • linker amino acid sequence -L- may be present or absent.
  • the hybrid may be NH 2 -X 1 -L 1 -X 2 -L 2 -COOH, NH 2 -X 1 -X 2 -COOH, NH 2 -X 1 -L 1 -X 2 -COOH, NH 2 -X 1 -X 2 -L 2 -COOH, etc.
  • Linker amino acid sequence(s) -L- will typically be short (e.g. 20 or fewer amino acids i.e. 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1).
  • Other suitable linker amino acid sequences will be apparent to those skilled in the art.
  • a useful linker is GSGGGG (SEQ ID NO: 15) or GSGSGGGG (SEQ ID NO:16), with the Gly-Ser dipeptide being formed from a BamHI restriction site, thus aiding cloning and manipulation, and the (Gly) 4 tetrapeptide being a typical poly-glycine linker.
  • Another suitable linker, particularly for use as the final L n is a Leu-Glu dipeptide.
  • -A- is an optional N-terminal amino acid sequence.
  • This will typically be short (e.g. 40 or fewer amino acids i.e. 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1).
  • Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art.
  • -A- is preferably an oligopeptide (e.g. with 1, 2, 3, 4, 5, 6, 7 or 8 amino acids) which provides a N-terminus methionine e.g. Met-Ala-Ser, or a single Met residue.
  • -B- is an optional C-terminal amino acid sequence.
  • This will typically be short (e.g. 40 or fewer amino acids i.e. 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1).
  • Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.
  • compositions of the first and second aspects include a fHbp antigen comprising an amino acid sequence having at least 99% sequence identity (e.g. 100% identity) to SEQ ID NO: 25.
  • This can be a third antigen in the first aspect and a second antigen in the second aspect.
  • This antigen can be a lipoprotein with a N-terminal cysteine.
  • compositions of the invention are adjuvanted.
  • the compositions include the adjuvant known as aluminium phosphate. This name is conventional, but is used for convenience only, as it is not a precise description of the actual chemical compound which is present (e.g. see chapter 9 of reference 28).
  • the invention can use any of the “phosphate” adjuvants that are in general use.
  • aluminium hydroxyphosphates typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Aluminium phosphates generally have a PO 4 /Al molar ratio between 0.3 and 1.2. Aluminium phosphates can be distinguished from strict AlPO 4 by the presence of hydroxyl groups. For example, an IR spectrum band at 3164 cm ⁇ 1 (e.g. when heated to 200° C.) indicates the presence of structural hydroxyls.
  • the aluminium phosphate adjuvant may contain a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate) and may also include sodium and/or chloride ions [29].
  • the adjuvant may be obtained by precipitation.
  • Aluminium hydroxyphosphate is not a stoichiometric compound and its hydroxyl and phosphate composition depends on precipitation reactants and conditions. This hydroxyl/phosphate composition affects the adjuvant's point of zero charge (PZC; the pH at which a surface has zero net charge).
  • PZC the adjuvant's point of zero charge
  • the PZC is inversely related to the degree of substitution of phosphate for hydroxyl (the P/Al molar ratio). Substitution of phosphate anions for hydroxyl anions lowers the PZC.
  • Aluminium phosphates used with the invention generally have a PZC of between 5.0 and 6.6 e.g. between 5.4 and 6.2.
  • the P/Al molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, or between 0.85 and 1.0, and more preferably about 0.9.
  • a P/Al molar ratio of at least 0.5 can provide an adjuvant with better aging properties.
  • the aluminium phosphate will generally be amorphous (i.e. amorphous to X-rays). It will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the plates are 10-100 nm, and these form aggregates sized 0.5-20 ⁇ m (e.g. about 1-10 ⁇ m). Adsorptive capacities of between 0.7-1.5 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
  • a typical adjuvant is amorphous aluminium hydroxyphosphate with P/Al molar ratio between 0.84 and 0.92, and this adjuvant may be included at 0.6 mg Al 3+ /ml.
  • the concentration of Al +++ in a composition for administration to a patient is preferably less than 5 mg/ml e.g. ⁇ 4 mg/ml, ⁇ 3 mg/ml, ⁇ 2 mg/ml, ⁇ 1 mg/ml, etc.
  • a preferred range is between 0.2 and 1 mg/ml.
  • a maximum Al +++ concentration of 0.85 mg/dose is preferred.
  • a composition should not include any aluminium hydroxide adjuvant because, as described above, it can degrade certain antigens which may be admixed with the fHbp (in particular, conjugated bacterial capsular saccharides). Instead, it is preferred to use only an aluminium phosphate adjuvant.
  • At least 75% (by weight) of fHbp in a composition of the invention should be adsorbed to it/them e.g. ⁇ 80%, ⁇ 75% ⁇ 90%, ⁇ 95% or even 100%.
  • the proportion of adsorbed fHbp can be controlled by altering salt concentration and/or pH during formulation e.g. in general, a higher NaCl concentration can decrease fHbp's adsorption.
  • the amount of adsorption for any formulation will depend on a combination of parameters including the adjuvant's PZC, the salt concentration and pH during formulation, the adjuvant concentration, the antigen concentration and the antigen's pI.
  • the impact of each of these parameters on adsorption can be readily assessed.
  • the degree of adsorption can be determined by comparing the total amount of fHbp antigen in a composition (e.g. measured before adsorption occurs, or measured by desorbing adsorbed antigen) to the amount which remains in the supernatant after centrifugation (e.g. see chapter 4 of ref 31).
  • the absence of detectable antigen in the supernatant after centrifugation indicates that total adsorption has occurred i.e. all of the fHbp is in the pellet, which contains the insoluble adjuvant and its adsorbed content.
  • Efficient adsorption of fHbp antigens can use the techniques disclosed in reference 32.
  • compositions of the invention can include further antigens from meningococcus or from other pathogens e.g. from other bacteria such as pneumococcus.
  • a composition may include one or more further meningococcal polypeptide antigen(s).
  • a composition may include a polypeptide antigen selected from the group consisting of: 287, NadA, NspA, HmbR, NhhA, App, and/or Omp85. These antigens will usefully be present as purified polypeptides e.g. recombinant polypeptides. The antigen will preferably elicit bactericidal anti-meningococcal antibodies after administration to a subject. If a composition includes a PorA antigen then, in some embodiments, only one meningococcal PorA serosubtype is included. In some embodiments, no meningococcal PorA outer membrane protein is included in a composition.
  • a composition of the invention may include a 287 antigen.
  • the 287 antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB2132 (GenBank accession number GI:7227388; SEQ ID NO: 9 herein).
  • the sequences of 287 antigen from many strains have been published since then.
  • allelic forms of 287 can be seen in FIGS. 5 and 15 of reference 33, and in example 13 and FIG. 21 of reference 34 (SEQ IDs 3179 to 3184 therein).
  • Various immunogenic fragments of the 287 antigen have also been reported.
  • Preferred 287 antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 9 SEQ ID NO: 9; and/or (b) comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 9, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 9.
  • the most useful 287 antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 9.
  • Advantageous 287 antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a composition of the invention may include a NadA antigen.
  • the NadA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB1994 (GenBank accession number GI:7227256; SEQ ID NO: 10 herein).
  • the sequences of NadA antigen from many strains have been published since then, and the protein's activity as a Neisserial adhesin has been well documented.
  • Various immunogenic fragments of NadA have also been reported.
  • Preferred NadA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 10 SEQ ID NO: 10
  • (b) comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 10, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 10.
  • the most useful NadA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 10.
  • Advantageous NadA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a useful NadA antigen for use with the invention has amino acid sequence SEQ ID NO: 49.
  • a composition of the invention may include a NspA antigen.
  • the NspA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB0663 (GenBank accession number GI:7225888; SEQ ID NO: 11 herein). The antigen was previously known from references 35 & 36. The sequences of NspA antigen from many strains have been published since then. Various immunogenic fragments of NspA have also been reported.
  • Preferred NspA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 11 comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 11, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 11.
  • the most useful NspA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 11.
  • Advantageous NspA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • compositions of the invention may include a meningococcal HmbR antigen.
  • the full-length HmbR sequence was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB1668 (SEQ ID NO: 7 herein).
  • Reference 37 reports a HmbR sequence from a different strain (SEQ ID NO: 8 herein).
  • SEQ ID NOs: 7 and 8 differ in length by 1 amino acid and have 94.2% identity.
  • the invention can use a polypeptide that comprises a full-length HmbR sequence, but it will often use a polypeptide that comprises a partial HmbR sequence.
  • a HmbR sequence used according to the invention may comprise an amino acid sequence having at least i % sequence identity to SEQ ID NO: 7, where the value of i is 50, 60, 70, 80, 90, 95, 99 or more.
  • a HmbR sequence used according to the invention may comprise a fragment of at least j consecutive amino acids from SEQ ID NO: 7, where the value of j is 7, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more.
  • a HmbR sequence used according to the invention may comprise an amino acid sequence (i) having at least i % sequence identity to SEQ ID NO: 7 and/or (ii) comprising a fragment of at least j consecutive amino acids from SEQ ID NO: 7.
  • Preferred fragments of j amino acids comprise an epitope from SEQ ID NO: 7.
  • Such epitopes will usually comprise amino acids that are located on the surface of HmbR.
  • Useful epitopes include those with amino acids involved in HmbR's binding to haemoglobin, as antibodies that bind to these epitopes can block the ability of a bacterium to bind to host haemoglobin.
  • HmbR antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 7.
  • Advantageous HmbR antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a composition of the invention may include a NhhA antigen.
  • the NhhA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB0992 (GenBank accession number GI:7226232; SEQ ID NO: 12 herein).
  • the sequences of NhhA antigen from many strains have been published since e.g. refs 33 & 39, and various immunogenic fragments of NhhA have been reported. It is also known as Hsf.
  • Preferred NhhA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 12 comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 12, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 12.
  • the most useful NhhA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 12.
  • Advantageous NhhA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a composition of the invention may include an App antigen.
  • the App antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB1985 (GenBank accession number GI:7227246; SEQ ID NO: 13 herein). The sequences of App antigen from many strains have been published since then. Various immunogenic fragments of App have also been reported.
  • Preferred App antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 13 comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 13, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 13.
  • the most useful App antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 13.
  • Advantageous App antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a composition of the invention may include an Omp85 antigen.
  • the Omp85 antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [9] as gene NMB0182 (GenBank accession number GI:7225401; SEQ ID NO: 14 herein). The sequences of Omp85 antigen from many strains have been published since then. Further information on Omp85 can be found in references 40 and 41. Various immunogenic fragments of Omp85 have also been reported.
  • Preferred Omp85 antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g.
  • SEQ ID NO: 14 comprising a fragment of at least ‘n’ consecutive amino acids of SEQ ID NO: 14, wherein ‘n’ is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 14.
  • the most useful Omp85 antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 14.
  • Advantageous Omp85 antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • a composition may include one or more meningococcal lipooligosaccharide (LOS) antigen(s).
  • Meningococcal LOS is a glucosamine-based phospholipid that is found in the outer monolayer of the outer membrane of the bacterium. It includes a lipid A portion and a core oligosaccharide region, with the lipid A portion acting as a hydrophobic anchor in the membrane. Heterogeneity within the oligosaccharide core generates structural and antigenic diversity among different meningococcal strains, which has been used to subdivide the strains into 12 immunotypes (L1 to L12).
  • the invention may use LOS from any immunotype e.g. from L1, L2, L3, L4, L5, L6, L7 and/or L8.
  • the L2 and L3 ⁇ -chains naturally include lacto-N-neotetraose (LNnT). Where the invention uses LOS from a L2 or L3 immunotype this LNnT may be absent. This absence can be achieved conveniently by using mutant strains that are engineered to disrupt their ability to synthesise the LNnT tetrasaccharide within the ⁇ -chain. It is known to achieve this goal by knockout of the enzymes that are responsible for the relevant biosynthetic additions [42,43]. For instance, knockout of the LgtB enzyme prevents addition of the terminal galactose of LNnT, as well as preventing downstream addition of the ⁇ -chain's terminal sialic acid.
  • LgtB enzyme prevents addition of the terminal galactose of LNnT, as well as preventing downstream addition of the ⁇ -chain's terminal sialic acid.
  • Knockout of the LgtA enzyme prevents addition of the N-acetyl-glucosamine of LNnT, and also the downstream additions.
  • LgtA knockout may be accompanied by LgtC knockout.
  • knockout of the LgtE and/or GalE enzyme prevents addition of internal galactose
  • knockout of LgtF prevents addition of glucose to the Hep I residue. Any of these knockouts can be used, singly or in combination, to disrupt the LNnT tetrasaccharide in a L2, L3, L4, L7 or L9 immunotype strain.
  • Knockout of at least LgtB is preferred, as this provides a LOS that retains useful immunogenicity while removing the LNnT epitope.
  • a knockout of the galE gene also provides a useful modified LOS, and a lipid A fatty transferase gene may similarly be knocked out [44].
  • At least one primary O-linked fatty acid may be removed from LOS [45].
  • LOS having a reduced number of secondary acyl chains per LOS molecule can also be used [46].
  • the LOS will typically include at least the GlcNAc-Hep 2 phosphoethanolamine-KDO 2 -Lipid A structure [47].
  • the LOS may include a GlcNAc ⁇ 1-3Gal ⁇ 1-4Glc trisaccharide while lacking the LNnT tetrasaccharide.
  • LOS may be included in compositions of the invention in various forms. It may be used in purified form on its own. It may be conjugated to a carrier protein. When LOS is conjugated, conjugation may be via a lipid A portion in the LOS or by any other suitable moiety e.g. its KDO residues. If the lipid A moiety of LOS is absent then such alternative linking is required. Conjugation techniques for LOS are known from e.g. references 45, 47, 48, 49, etc. Useful carrier proteins for these conjugates are discussed below e.g. bacterial toxins, such as diphtheria or tetanus toxins, or toxoids or mutants thereof.
  • the LOS may be from a strain (e.g. a genetically-engineered meningococcal strain) which has a fixed (i.e. not phase variable) LOS immunotype as described in reference 50.
  • a strain e.g. a genetically-engineered meningococcal strain
  • L2 and L3 LOS immunotypes may be fixed.
  • Such strains may have a rate of switching between immunotypes that is reduced by more than 2-fold (even >50 fold) relative to the original wild-type strain.
  • Reference 50 discloses how this result can be achieved by modification of the lgtA and/or lgtG gene products.
  • LOS may be O-acetylated on a GlcNac residue attached to its Heptose II residue e.g. for L3 [51].
  • An immunogenic composition can include more than one type of LOS e.g. LOS from meningococcal immunotypes L2 and L3.
  • LOS e.g. LOS from meningococcal immunotypes L2 and L3.
  • the LOS combinations disclosed in reference 52 may be used.
  • a LOS antigen can preferably elicit bactericidal anti-meningococcal antibodies after administration to a subject.
  • compositions of the invention are free from meningococcal lipooligosaccharide.
  • a composition may include one or more meningococcal capsular saccharide conjugates.
  • a composition of the invention may include one or more conjugates of capsular saccharides from 1, 2, 3, or 4 of meningococcal serogroups A, C, W135 and Y e.g. A+C, A+W135, A+Y, C+W135, C+Y, W135+Y, A+C+W135, A+C+Y, A+W135+Y, A+C+W135+Y, etc.
  • Compositions including a conjugated serogroup C capsular saccharide are useful, and compositions including saccharides from all of serogroups A, C, W135 and Y are ideal.
  • the capsular saccharide of serogroup A meningococcus is a homopolymer of ( ⁇ 1 ⁇ 6)-linked N-acetyl-D-mannosamine-1-phosphate, with partial O-acetylation in the C3 and C4 positions. Acetylation at the C-3 position can be 70-95%. Conditions used to purify the saccharide can result in de-O-acetylation (e.g. under basic conditions), but it is useful to retain OAc at this C-3 position. In some embodiments, at least 50% (e.g. at least 60%, 70%, 80%, 90%, 95% or more) of the mannosamine residues in a serogroup A saccharides are O-acetylated at the C-3 position. Acetyl groups can be replaced with blocking groups to prevent hydrolysis [53], and such modified saccharides are still serogroup A saccharides within the meaning of the invention.
  • the serogroup C capsular saccharide is a homopolymer of ( ⁇ 2 ⁇ 9)-linked sialic acid (N-acetyl neuraminic acid, or ‘NeuNAc’).
  • the saccharide structure is written as ⁇ 9)-Neu p NAc 7/8 OAc-( ⁇ 2 ⁇ .
  • Most serogroup C strains have O-acetyl groups at C-7 and/or C-8 of the sialic acid residues, but about 15% of clinical isolates lack these O-acetyl groups [54,55].
  • OAc+ O-acetylated
  • OAc ⁇ de-O-acetylated
  • Serogroup C saccharides used with the invention may be prepared from either OAc+ or OAc ⁇ strains.
  • Licensed MenC conjugate vaccines include both OAc ⁇ (NEISVAC-CTM) and OAc+(MENJUGATETM & MENINGITECTM) saccharides.
  • strains for production of serogroup C conjugates are OAc+ strains, e.g. of serotype 16, serosubtype P1.7a,1, etc.
  • C:16:P1.7a,1 OAc+ strains may be used.
  • OAc+ strains in serosubtype P1.1 are also useful, such as the C11 strain.
  • the serogroup W135 saccharide is a polymer of sialic acid-galactose disaccharide units. Like the serogroup C saccharide, it has variable O-acetylation, but at sialic acid 7 and 9 positions [59].
  • the structure is written as: ⁇ 4)-D-Neup5Ac(7/90Ac)- ⁇ -(2 ⁇ 6)-D-Gal- ⁇ -(1 ⁇ .
  • the serogroup Y saccharide is similar to the serogroup W135 saccharide, except that the disaccharide repeating unit includes glucose instead of galactose. Like serogroup W135, it has variable O-acetylation at sialic acid 7 and 9 positions [59].
  • the serogroup Y structure is written as: ⁇ 4)-D-Neup5Ac(7/90Ac)- ⁇ -(2 ⁇ 6)-D-Glc- ⁇ -(1 ⁇ .
  • the saccharides used according to the invention may be O-acetylated as described above (e.g. with the same O-acetylation pattern as seen in native capsular saccharides), or they may be partially or totally de-O-acetylated at one or more positions of the saccharide rings, or they may be hyper-O-acetylated relative to the native capsular saccharides.
  • the saccharide moieties in conjugates may comprise full-length saccharides as prepared from meningococci, and/or may comprise fragments of full-length saccharides i.e. the saccharides may be shorter than the native capsular saccharides seen in bacteria.
  • the saccharides may thus be depolymerised, with depolymerisation occurring during or after saccharide purification but before conjugation. Depolymerisation reduces the chain length of the saccharides.
  • One depolymerisation method involves the use of hydrogen peroxide. Hydrogen peroxide is added to a saccharide (e.g. to give a final H 2 O 2 concentration of 1%), and the mixture is then incubated (e.g.
  • saccharides used to prepare conjugates for use according to the invention may be obtainable by any of these depolymerisation methods.
  • Depolymerisation can be used in order to provide an optimum chain length for immunogenicity and/or to reduce chain length for physical manageability of the saccharides.
  • useful ranges are, for all serogroups: ⁇ 100 kDa; 5 kDa-75 kDa; 7 kDa-50 kDa; 8 kDa-35 kDa; 12 kDa-25 kDa; 15 kDa-22 kDa.
  • the average molecular weight for saccharides from each of meningococcal serogroups A, C, W135 and Y may be more than 50 kDa e.g. ⁇ 75 kDa, ⁇ 100 kDa, ⁇ 110 kDa, ⁇ 120 kDa, ⁇ 130 kDa, etc. [60], and even up to 1500 kDa, in particular as determined by MALLS.
  • a MenA saccharide may be in the range 50-500 kDa e.g.
  • a MenC saccharide may be in the range 100-210 kDa
  • a MenW135 saccharide may be in the range 60-190 kDa e.g. 120-140 kDa
  • a MenY saccharide may be in the range 60-190 kDa e.g.150-160 kDa.
  • the mass of meningococcal saccharide per serogroup in a composition will usually be between 1 ⁇ g and 20 ⁇ g e.g. between 2 and 10 ⁇ g per serogroup, or about 4 ⁇ g or about 5 ⁇ g or about 10 ⁇ g. Where conjugates from more than one serogroup are included then they may be present at substantially equal masses e.g. the mass of each serogroup's saccharide is within +10% of each other. As an alternative to an equal ratio, a double mass of serogroup A saccharide may be used.
  • a vaccine may include MenA saccharide at 10 ⁇ g and MenC, W135 and Y saccharides at 5 ⁇ g each.
  • Useful carrier proteins for meningococcal conjugates include bacterial toxins, such as diphtheria or tetanus toxins, or toxoids or mutants thereof. These are commonly used in conjugate vaccines.
  • the CRM197 diphtheria toxin mutant is useful [61].
  • Other suitable carrier proteins include synthetic peptides [62,63], heat shock proteins [64,65], pertussis proteins [66,67], cytokines [68], lymphokines [68], hormones [68], growth factors [68], artificial proteins comprising multiple human CD4 + T cell epitopes from various pathogen-derived antigens [69] such as N19 [70], protein D from H.
  • composition includes conjugates from more than one meningococcal serogroup it is possible to use the same carrier protein for each separate conjugate, or to use different carrier proteins. In both cases, though, a mixture of different conjugates will usually be formed by preparing each serotype conjugate separately, and then mixing them to form a mixture of separate conjugates.
  • Conjugates with a saccharide:protein ratio (w/w) of between 1:5 (i.e. excess protein) and 5:1 (i.e. excess saccharide) may be used e.g. ratios between 1:2 and 5:1 and ratios between 1:1.25 and 1:2.5.
  • different meningococcal serogroup conjugates in a mixture can have different saccharide:protein ratios e.g. one may have a ratio of between 1:2 & 1:5, whereas another has a ratio between 5:1 & 1:1.99.
  • a carrier protein may be covalently conjugated to a meningococcal saccharide directly or via a linker.
  • Various linkers are known. For example, attachment may be via a carbonyl, which may be formed by reaction of a free hydroxyl group of a modified saccharide with CDI [81,82] followed by reaction with a protein to form a carbamate linkage. Carbodiimide condensation can be used [83].
  • An adipic acid linker can be used, which may be formed by coupling a free —NH 2 group (e.g.
  • linkers include ⁇ -propionamido [86], nitrophenyl-ethylamine [87], haloacyl halides [88], glycosidic linkages [89], 6-aminocaproic acid [90], N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) [91], adipic acid dihydrazide ADH [92], C 4 to C 12 moieties [93], etc.
  • SPDP N-succinimidyl-3-(2-pyridyldithio)-propionate
  • Conjugation via reductive amination can be used.
  • the saccharide may first be oxidised with periodate to introduce an aldehyde group, which can then form a direct covalent linkage to a carrier protein via reductive amination e.g. to the ⁇ -amino group of a lysine. If the saccharide includes multiple aldehyde groups per molecule then this linkage technique can lead to a cross-linked product, where multiple aldehydes react with multiple carrier amines.
  • a mixture can include one conjugate with direct saccharide/protein linkage and another conjugate with linkage via a linker.
  • This arrangement applies particularly when using saccharide conjugates from different meningococcal serogroups e.g. MenA and MenC saccharides may be conjugated via a linker, whereas MenW135 and MenY saccharides may be conjugated directly to a carrier protein.
  • a meningococcal saccharide may comprise a full-length intact saccharide as prepared from meningococcus, and/or may comprise fragments of full-length saccharides i.e. the saccharides may be shorter than the native capsular saccharides seen in bacteria.
  • the saccharides may thus be depolymerised, with depolymerisation occurring during or after saccharide purification but before conjugation. Depolymerisation reduces the chain length of the saccharides. Depolymerisation can be used in order to provide an optimum chain length for immunogenicity and/or to reduce chain length for physical manageability of the saccharides.
  • compositions of the invention may include a pneumococcal capsular saccharide conjugated to a carrier protein.
  • the invention can include capsular saccharide from one or more different pneumococcal serotypes. Where a composition includes saccharide antigens from more than one serotype, these are preferably prepared separately, conjugated separately, and then combined. Methods for purifying pneumococcal capsular saccharides are known in the art (e.g. see reference 95) and vaccines based on purified saccharides from 23 different serotypes have been known for many years. Improvements to these methods have also been described e.g. for serotype 3 as described in reference 96, or for serotypes 1, 4, 5, 6A, 6B, 7F and 19A as described in reference 97.
  • Pneumococcal capsular saccharide(s) will typically be selected from the following serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and/or 33F.
  • a composition may include a capsular saccharide from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or more different serotypes.
  • a useful combination of serotypes is a 7-valent combination e.g. including capsular saccharide from each of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
  • Another useful combination is a 9-valent combination e.g. including capsular saccharide from each of serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F.
  • Another useful combination is a 10-valent combination e.g. including capsular saccharide from each of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
  • An 11-valent combination may further include saccharide from serotype 3.
  • a 12-valent combination may add to the 10-valent mixture: serotypes 6A and 19A; 6A and 22F; 19A and 22F; 6A and 15B; 19A and 15B; or 22F and 15B.
  • a 13-valent combination may add to the 11-valent mixture: serotypes 19A and 22F; 8 and 12F; 8 and 15B; 8 and 19A; 8 and 22F; 12F and 15B; 12F and 19A; 12F and 22F; 15B and 19A; 15B and 22F; 6A and 19A, etc.
  • a useful 13-valent combination includes capsular saccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19, 19F and 23F e.g. prepared as disclosed in references 98 to 101.
  • One such combination includes serotype 6B saccharide at about 8 ⁇ g/ml and the other 12 saccharides at concentrations of about 4 ⁇ g/ml each.
  • Another such combination includes serotype 6A and 6B saccharides at about 8 ⁇ g/ml each and the other 11 saccharides at about 4 ⁇ g/ml each.
  • Suitable carrier proteins for conjugates are discussed above in relation to meningococcal conjugates.
  • Particularly useful carrier proteins for pneumococcal conjugate vaccines are CRM197, tetanus toxoid, diphtheria toxoid and H. influenzae protein D.
  • CRM197 is used in PREVNARTM.
  • a 13-valent mixture may use CRM197 as the carrier protein for each of the 13 conjugates, and CRM197 may be present at about 55-60 ⁇ g/ml.
  • composition includes conjugates from more than one pneumococcal serotype
  • a mixture of different conjugates will usually be formed by preparing each serotype conjugate separately, and then mixing them to form a mixture of separate conjugates.
  • Reference 102 describes potential advantages when using different carrier proteins in multivalent pneumococcal conjugate vaccines, but the PREVNARTM product successfully uses the same carrier for each of seven different serotypes.
  • a carrier protein may be covalently conjugated to a pneumococcal saccharide directly or via a linker, as discussed above in relation to meningococcal conjugates.
  • Cross-linking conjugation techniques are particularly useful for at least pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
  • a pneumococcal saccharide may comprise a full-length intact saccharide as prepared from pneumococcus, and/or may comprise fragments of full-length saccharides.
  • a pneumococcal serotype is used then it is possible to use intact saccharides for each serotype, fragments for each serotype, or to use intact saccharides for some serotypes and fragments for other serotypes.
  • a composition includes saccharide from any of serotypes 4, 6B, 9V, 14, 19F and 23F, these saccharides are preferably intact.
  • serotype 18C saccharide it is preferably depolymerised.
  • a serotype 3 saccharide may also be depolymerised, For instance, a serotype 3 saccharide can be subjected to acid hydrolysis for depolymerisation [98] e.g. using acetic acid. The resulting fragments may then be oxidised for activation (e.g. periodate oxidation, maybe in the presence of bivalent cations e.g. with MgCl 2 ), conjugated to a carrier (e.g. CRM197) under reducing conditions (e.g. using sodium cyanoborohydride), and then (optionally) any unreacted aldehydes in the saccharide can be capped (e.g. using sodium borohydride) [98]. Conjugation may be performed on lyophilized material e.g. after co-lyophilizing activated saccharide and carrier.
  • acid hydrolysis for depolymerisation [98] e.g. using acetic acid.
  • the resulting fragments may then be oxidised for activation (e.g
  • a serotype 1 saccharide may be at least partially de-O-acetylated e.g. achieved by alkaline pH buffer treatment [99] such as by using a bicarbonate/carbonate buffer.
  • Such (partially) de-O-acetylated saccharides can be oxidised for activation (e.g. periodate oxidation), conjugated to a carrier (e.g. CRM197) under reducing conditions (e.g. using sodium cyanoborohydride), and then (optionally) any unreacted aldehydes in the saccharide can be capped (e.g. using sodium borohydride) [99].
  • Conjugation may be performed on lyophilized material e.g. after co-lyophilizing activated saccharide and carrier.
  • a serotype 19A saccharide may be oxidised for activation (e.g. periodate oxidation), conjugated to a carrier (e.g. CRM197) in DMSO under reducing conditions, and then (optionally) any unreacted aldehydes in the saccharide can be capped (e.g. using sodium borohydride) [103]. Conjugation may be performed on lyophilized material e.g. after co-lyophilizing activated saccharide and carrier.
  • a carrier e.g. CRM197
  • Conjugation may be performed on lyophilized material e.g. after co-lyophilizing activated saccharide and carrier.
  • Pneumococcal conjugates can ideally elicit anticapsular antibodies that bind to the relevant saccharide e.g. elicit an anti-saccharide antibody level ⁇ 0.20 ⁇ g/mL [104].
  • the antibodies may be evaluated by enzyme immunoassay (EIA) and/or measurement of opsonophagocytic activity (OPA).
  • EIA enzyme immunoassay
  • OPA opsonophagocytic activity
  • compositions of the invention can include antigen(s) from further pathogen(s).
  • the composition may comprise one or more of the following further antigen(s):
  • diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. DTP combinations are thus preferred.
  • the invention also provides a kit comprising: (i) a first component comprising fHbp antigens, as described above; and (ii) a second component comprising a non-meningococcal immunogen.
  • kit components can be mixed to give an immunogenic composition for administering to a patient to protect against multiple pathogens.
  • the invention also provides a method for preparing a combined vaccine, comprising a step of mixing: (i) a first component comprising fHbp antigens, as described above; and (ii) a second component comprising a non-meningococcal immunogen.
  • the mixed material may then be administered to a patient.
  • the second component may be lyophilised, such that an aqueous first component reconstitutes it.
  • compositions for administration to a patient.
  • These compositions are pharmaceutically acceptable and will typically include a suitable carrier.
  • a thorough discussion of pharmaceutically acceptable carriers is available in reference 105.
  • Effective dosage volumes can be routinely established, but a typical human unit dose of the composition has a volume of about 0.5 ml.
  • the total amount of a fHbp polypeptide in a unit dose will usually be between 1 and 500 ⁇ g/dose e.g. between 60 and 200 ⁇ g/dose or between 120 and 500 ⁇ g/ml.
  • An amount of 20, 40, 50, 60, 80, 100 or 200 ⁇ g for each fHbp antigen is typical in a human vaccine dose.
  • a vaccine may be formulated to include this amount of each fHbp.
  • compositions may include a buffer e.g. a Tris buffer, a citrate buffer, a succinate buffer (such as a sodium succinate buffer), or a histidine buffer.
  • a buffer e.g. a Tris buffer, a citrate buffer, a succinate buffer (such as a sodium succinate buffer), or a histidine buffer.
  • composition may be sterile and/or pyrogen-free.
  • Compositions of the invention may be isotonic with respect to humans.
  • compositions of the invention may include sodium salts (e.g. sodium chloride) to give tonicity.
  • sodium salts e.g. sodium chloride
  • a concentration of 10 ⁇ 2 mg/ml NaCl is typical e.g. about 9 mg/ml.
  • compositions of the invention for administration to patients are immunogenic, and are more preferably vaccine compositions.
  • Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic.
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed.
  • immunologically effective amount it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g.
  • compositions of the invention will generally be expressed in terms of the amount of protein per dose.
  • compositions of the invention may be prepared in various liquid forms.
  • the compositions may be prepared as injectables, either as solutions or suspensions.
  • the composition may be prepared for pulmonary administration e.g. by an inhaler, using a fine spray.
  • the composition may be prepared for nasal, aural or ocular administration e.g. as spray or drops. Injectables for intramuscular administration are most typical.
  • compositions of the invention may include an antimicrobial, particularly when packaged in multiple dose format.
  • Antimicrobials such as thiomersal and 2-phenoxyethanol are commonly found in vaccines, but it is preferred to use either a mercury-free preservative or no preservative at all.
  • compositions of the invention may comprise detergent e.g. a polysorbate (TWEEN), such as polysorbate 80.
  • TWEEN polysorbate
  • Detergents are generally present at low levels e.g. ⁇ 0.01%, but higher levels have been suggested for stabilising antigen formulations [106] e.g. up to 10%.
  • An example composition may include from 0.01 to 0.05% polysorbate, and this is particularly useful when using lipidated fHbp antigen(s).
  • the invention also provides a method for raising an immune response in a mammal, comprising administering a composition of the invention to the mammal.
  • the immune response is preferably protective against meningococcus and preferably involves antibodies.
  • the method may raise a booster response in a patient that has already been primed.
  • the mammal is preferably a human.
  • the human is preferably a child (e.g. a toddler or infant) or a teenager; where the vaccine is for therapeutic use, the human is preferably an adult.
  • a vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc.
  • the invention also provides compositions of the invention for use as a medicament.
  • the medicament is preferably used, as described above, to raise an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine.
  • the invention also provides the use of at least two fHbp antigens, as defined above, in the manufacture of a medicament for raising an immune response, as described above, in a mammal.
  • N. meningitidis e.g. bacterial (or, more specifically, meningococcal) meningitis, or septicemia.
  • One way of checking efficacy of therapeutic treatment involves monitoring meningococcal infection after administration of the composition of the invention.
  • One way of checking efficacy of prophylactic treatment involves monitoring immune responses against antigens after administration of the composition. Immunogenicity of compositions of the invention can be determined by administering them to test subjects (e.g. children 12-16 months age, or animal models) and then determining standard parameters including serum bactericidal antibodies (SBA) and ELISA titres (GMT) for meningococcus. These immune responses will generally be determined around 4 weeks after administration of the composition, and compared to values determined before administration of the composition. A SBA increase of at least 4-fold or 8-fold is preferred. Where more than one dose of the composition is administered, more than one post-administration determination may be made.
  • compositions of the invention will generally be administered directly to a patient.
  • Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by any other suitable route.
  • the invention may be used to elicit systemic and/or mucosal immunity.
  • Intramuscular administration to the thigh or the upper arm is preferred. Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used.
  • a typical intramuscular dose is 0.5 ml.
  • Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. A primary dose schedule may be followed by a booster dose schedule. Suitable timing between priming doses (e.g. between 4-16 weeks), and between priming and boosting, can be routinely determined.
  • composition “comprising” encompasses “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X+Y.
  • this epitope may be a B-cell epitope and/or a T-cell epitope, but will usually be a B-cell epitope.
  • Such epitopes can be identified empirically (e.g. using PEPSCAN [114,115] or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index [116], matrix-based approaches [117], MAPITOPE [118], TEPITOPE [119,120], neural networks [121], OptiMer & EpiMer [122,123], ADEPT [124], Tsites [125], hydrophilicity [126], antigenic index [127] or the methods disclosed in references 128-132, etc.).
  • Epitopes are the parts of an antigen that are recognised by and bind to the antigen binding sites of antibodies or T-cell receptors, and they may also be referred to as “antigenic determinants”.
  • this antigen is separated from its naturally occurring environment.
  • the antigen will be substantially free from other meningococcal components, other than from any other purified antigens that are present.
  • a mixture of purified antigens will typically be prepared by purifying each antigen separately and then re-combining them, even if the two antigens are naturally present in admixture.
  • references to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences.
  • This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. 133.
  • a preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62.
  • the Smith-Waterman homology search algorithm is disclosed in ref 134.
  • GI numbering is used above.
  • a GI number, or “GenInfo Identifier”, is a series of digits assigned consecutively to each sequence record processed by NCBI when sequences are added to its databases. The GI number bears no resemblance to the accession number of the sequence record.
  • a sequence is updated (e.g. for correction, or to add more annotation or information) then it receives a new GI number. Thus the sequence associated with a given GI number is never changed.
  • FIG. 1 shows adsorption of fHbp antigens to aluminium hydroxide (AH) or aluminium phosphate (AP) adjuvants.
  • Lanes marked “D” are antigen after desorption treatment, whereas “T” lanes are the solution-phase antigens after adsorption.
  • AH aluminium hydroxide
  • AP aluminium phosphate
  • FIG. 2 is like FIG. 1 , but shows adsorption of fHbp mixtures.
  • FIG. 1 confirms that the individual fHbp antigens adsorbed well to both adjuvants, and could be desorbed intact.
  • FIG. 2 shows that this result was also seen with the bivalent mixtures.
  • the MC58 antigen was able to protect against the homologous strain with both adjuvants, but not against the other strains.
  • the M01240320 antigen was able to protect against the homologous strain with both adjuvants, and also against another family III strain, but did not protect against family I strains and could protect against family II strains when using an AH adjuvant.
  • the M01573 antigen alone did not protect against any of these six strains, with either adjuvant. Thus results were mixed with the monovalent vaccines.
  • the bivalent vaccine based on a combination of MC58 and M01240320 protected against all six strains (except for one strain when using the AP adjuvant), including family II strains.
  • a vaccine should either replace it, or supplement it with a second family I sequence e.g. M01573+MC58.
  • a combination of a sub-family I.1 sequence with a family III sequence can give broad protection using either an AH or an AP adjuvant.
  • SEQ ID NOs: 23 and 26 are mature amino acid sequences (N-terminal cysteine) from strains MC58 and M01573, respectively. They align as follows:
  • Val-8 of SEQ ID NO: 26 and Val-13 of SEQ ID NO: 23 are 87.5% identical (217/248 identical residues).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
US14/368,957 2011-12-29 2011-12-29 Adjuvanted combinations of meningococcal factor H binding proteins Active 2033-01-13 US10596246B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056006 WO2013098589A1 (en) 2011-12-29 2011-12-29 Adjuvanted combinations of meningococcal factor h binding proteins

Publications (2)

Publication Number Publication Date
US20150209419A1 US20150209419A1 (en) 2015-07-30
US10596246B2 true US10596246B2 (en) 2020-03-24

Family

ID=45529152

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/368,957 Active 2033-01-13 US10596246B2 (en) 2011-12-29 2011-12-29 Adjuvanted combinations of meningococcal factor H binding proteins

Country Status (7)

Country Link
US (1) US10596246B2 (enrdf_load_stackoverflow)
EP (1) EP2797624A1 (enrdf_load_stackoverflow)
JP (1) JP2015505309A (enrdf_load_stackoverflow)
AU (1) AU2011384634A1 (enrdf_load_stackoverflow)
BR (1) BR112014016223A8 (enrdf_load_stackoverflow)
CA (1) CA2862247A1 (enrdf_load_stackoverflow)
WO (1) WO2013098589A1 (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012045075A1 (en) 2010-10-01 2012-04-05 Jason Schrum Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
AU2016269722B2 (en) * 2015-06-02 2021-06-24 Intravacc B.V. Surface display of antigens on Gram-negative outer membrane vesicles

Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
EP0208375A2 (en) 1985-07-05 1987-01-14 SCLAVO S.p.A. Glycoproteinic conjugates having trivalent immunogenic activity
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
EP0378881A1 (en) 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4965338A (en) 1988-08-18 1990-10-23 General Electric Company PBT with improved tracking resistance
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
EP0427347A1 (en) 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
EP0471177A2 (en) 1990-08-13 1992-02-19 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
WO1993017712A2 (en) 1992-03-06 1993-09-16 Biocine Spa Conjugates formed from heat shock proteins and oligo- or polysaccharides
WO1994003208A1 (en) 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1994005325A1 (en) 1992-08-31 1994-03-17 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
WO1994008021A1 (en) 1992-10-02 1994-04-14 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom
EP0594610A1 (en) 1990-05-31 1994-05-04 Arne Forsgren PROTEIN D - AN IgD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
WO1996029412A1 (en) 1995-03-17 1996-09-26 Biochem Vaccines Inc. Proteinase k resistant surface protein of neisseria meningitidis
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
WO1998058668A2 (en) 1997-06-20 1998-12-30 Microbiological Research Authority Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
WO1999057280A2 (en) 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000023595A1 (en) 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
WO2000026384A1 (en) 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
WO2001022992A2 (en) 1999-09-30 2001-04-05 Smithkline Beecham Biologicals S.A. Influenza vaccine
WO2001038350A2 (en) 1999-11-29 2001-05-31 Chiron Spa 85kDa NEISSERIAL ANTIGEN
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
WO2001072337A1 (en) 2000-03-27 2001-10-04 Microbiological Research Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2003020756A2 (en) 2001-09-06 2003-03-13 Chiron Srl. Hybrid and tandem expression of neisserial proteins
WO2003063766A2 (en) 2001-10-11 2003-08-07 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2003070282A2 (en) 2002-02-22 2003-08-28 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
WO2004048404A2 (en) 2002-11-22 2004-06-10 Chiron Srl Multiple variants of meningococcal protein nmb1870
WO2004094596A2 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2005033148A1 (en) 2003-10-02 2005-04-14 Chiron Srl Hypo- and hyper-acetylated meningococcal capsular saccharides
WO2006024954A2 (en) 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
US20060228380A1 (en) 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228381A1 (en) 2005-04-08 2006-10-12 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
WO2007000341A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007060548A2 (en) 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2007071707A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184071A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007127665A2 (en) 2006-04-26 2007-11-08 Wyeth Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007144316A2 (en) 2006-06-12 2007-12-21 Glaxosmithkline Biologicals Sa Vaccine
US20080102498A1 (en) 2006-10-10 2008-05-01 Wyeth Methods for the separation of streptococcus pneumoniae type 3 polysaccharides
WO2008079372A2 (en) 2006-12-22 2008-07-03 Wyeth Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens

Patent Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
EP0208375A2 (en) 1985-07-05 1987-01-14 SCLAVO S.p.A. Glycoproteinic conjugates having trivalent immunogenic activity
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4965338A (en) 1988-08-18 1990-10-23 General Electric Company PBT with improved tracking resistance
EP0378881A1 (en) 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
EP0427347A1 (en) 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
EP0594610A1 (en) 1990-05-31 1994-05-04 Arne Forsgren PROTEIN D - AN IgD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE
EP0471177A2 (en) 1990-08-13 1992-02-19 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
WO1993017712A2 (en) 1992-03-06 1993-09-16 Biocine Spa Conjugates formed from heat shock proteins and oligo- or polysaccharides
WO1994003208A1 (en) 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
WO1994005325A1 (en) 1992-08-31 1994-03-17 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
WO1994008021A1 (en) 1992-10-02 1994-04-14 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
WO1996029412A1 (en) 1995-03-17 1996-09-26 Biochem Vaccines Inc. Proteinase k resistant surface protein of neisseria meningitidis
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
WO1998058668A2 (en) 1997-06-20 1998-12-30 Microbiological Research Authority Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
WO1999057280A2 (en) 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000023595A1 (en) 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
WO2000026384A1 (en) 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001022992A2 (en) 1999-09-30 2001-04-05 Smithkline Beecham Biologicals S.A. Influenza vaccine
WO2001038350A2 (en) 1999-11-29 2001-05-31 Chiron Spa 85kDa NEISSERIAL ANTIGEN
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
WO2001072337A1 (en) 2000-03-27 2001-10-04 Microbiological Research Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003020756A2 (en) 2001-09-06 2003-03-13 Chiron Srl. Hybrid and tandem expression of neisserial proteins
WO2003063766A2 (en) 2001-10-11 2003-08-07 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US8563006B2 (en) * 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2003070282A2 (en) 2002-02-22 2003-08-28 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004048404A2 (en) 2002-11-22 2004-06-10 Chiron Srl Multiple variants of meningococcal protein nmb1870
US20060251670A1 (en) * 2002-11-22 2006-11-09 Maurizio Comanducci Multiple variants of meningococcal protein nmb1870
WO2004094596A2 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2005033148A1 (en) 2003-10-02 2005-04-14 Chiron Srl Hypo- and hyper-acetylated meningococcal capsular saccharides
WO2006024954A2 (en) 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
US20060228380A1 (en) 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184071A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228381A1 (en) 2005-04-08 2006-10-12 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
WO2007000343A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
WO2007000342A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007000314A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007000341A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007060548A2 (en) 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2007071707A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
WO2007127665A2 (en) 2006-04-26 2007-11-08 Wyeth Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007144316A2 (en) 2006-06-12 2007-12-21 Glaxosmithkline Biologicals Sa Vaccine
WO2007144317A2 (en) 2006-06-12 2007-12-21 Glaxosmithlline Biologicals Sa Vaccine
US20080102498A1 (en) 2006-10-10 2008-05-01 Wyeth Methods for the separation of streptococcus pneumoniae type 3 polysaccharides
WO2008143709A2 (en) 2006-12-22 2008-11-27 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2008079372A2 (en) 2006-12-22 2008-07-03 Wyeth Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
US20130189295A1 (en) 2010-06-25 2013-07-25 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens

Non-Patent Citations (75)

* Cited by examiner, † Cited by third party
Title
Anderson et al., Poster Abstract No. P100 on pp. 170 to 171 entitled "Functional cross-reactive antibodies are elicited by a Group B Neisseria meningitidis bivalent recombinant lipidated LP2086 vaccine in Cynomolgus macaques" for the 16th International Pathogenic Neisseria Conference Jul. 7, 2008 in Rotterdam, The Netherlands, available at http://neisseria.org/ipnc/2008/Abstracts_poster_presentations_IPNC_2008.pdf (last visited Feb. 22, 2017).
Arakere et al., Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. Dec. 1991;59(12):4349-56.
Baraldo et al., N19 polyepitope as a carver for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect Immun. Aug. 2004;72(8):4884-7.
Beernink et al., Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol. Jul. 2006;13(7):758-63.
Bethell et al., A novel method of activation of cross-linked agaroses with 1,1′-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups. J Biol Chem. Apr. 25, 1979;254(8):2572-4.
Brunelli et al., Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1., 2011 Vaccine 3(91) : 1072-1081.
Brusic et al., Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics. 1998;14(2):121-30.
Bublil et al., Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins. Jul. 1, 2007;68(1):294-304.
Burrell et al., Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part I: composition and structure. Vaccine. Sep. 15, 2000;19(2-3):275-81.
Cantini et al., Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J Biol Chem. Mar. 17, 2006;281(11):7220-7.
Carter, J.M., Epitope mapping of a protein using the Geysen (PEPSCAN) procedure, Chapter 12 on pp. 207-223 in Methods Mol. Biol. vol. 36 1994 (eds. Dunn and Pennington, Humana Press Inc., Totowa NJ).
Chen et al., Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids. Sep. 2007;33(3):423-8.
Comanducci et al., NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. Jun. 3, 2002;195(11):1445-54.
Davenport et al., An empirical method for the prediction of T-cell epitopes. Immunogenetics. 1995;42(5):392-7.
De Lalla et al., Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction. J Immunol. Aug. 15, 1999;163(4):1725-9.
Dunning Hotopp et al., Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology. Dec. 2006;152(Pt 12)3733-49.
European Patent Office as International Preliminary Examining Authority, International Preliminary Report on Patentability for International Application No. PCT/IB2011/056006 dated Mar. 26, 2014; 23 total pages.
European Patent Office as International Search Authority, Written Opinion and International Search Report for International Application No. PCT/IB2011/056006 dated Nov. 13, 2012; 19 total pages.
Falugi et al., Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur J Immunol. Dec. 2001;31(12):3816-24.
Feller et al., Identifying antigenic T-cell sites. Nature. Feb. 21, 1991;349(6311):720-1.
Fletcher et al., Vaccine potential of the Neisseria meningitidis 2086 lipoprotein, 2004 Infect. Immun. &2(4): 2088-2100.
Frasch et al., Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. Jun. 24, 2009;27 Suppl 2:B112-6.
Geyer et al., Immunochemical properties of oligosaccharide-protein conjugates with Klebsiella-K2 specificity. I. Specificity and crossreactivity of anti-conjugate versus anti-bacterial antibodies. Med Microbiol Immunol. Jan. 24, 1979;165(4):271-88.
Geysen et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci U S A. Jul. 1984;81(13):3998-4002.
Giuliani et al., A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. Jul. 18, 2006;103(29):10834-9.
Giuliani et al., The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun. Feb. 2005;73(2):1151-60.
Glode et al., Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J Infect Dis. Jan. 1979;139(1):52-9.
Goldschneider et al., Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. Jun. 1, 1969;129(6):1307-26.
Granoff, D.M., Review of meningococcal group B vaccines, 2010 Clin. Infect. Dis. 50(S4): S54 ; 23 total pages.
Greenspan et al. Nature Biotechnology 17:936-937, 1999. *
Hearn et al., Application of 1,1′-carbonyldiimidazole-activated matrices for the purification of proteins. III. The use of 1,1′-carbonyldiimidazole-activated agaroses in the biospecific affinity chromatographic isolation of serum antibodies. J Chromatogr. Nov. 20, 1981;218:509-18.
Hou et al., Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis. Aug. 15, 2005;192(4):580-90.
Jameson et al., The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci. Mar. 1988;4(1):181-6.
Jiang et al., Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease, 2010 Vaccine 28: 6086-6093.
Jodar et al., Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. Jul. 4, 2003;21(23):3265-72.
Jones et al., Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens, 2005 Journal of Biological Chemistry 280(14): 13406-13414.
Koeberling et al., Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2, 2009 Clin. Vaccine Immunol. 16(2): 156-162.
Kuo et al., Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect Immun. Jul. 1995;63(7):2706-13.
Kwok et al., Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol. Nov. 2001;22(11):583-8.
Lazar et al. Mol. Cellular Biol. 8: 1247-1252, 1988. *
Maksyutov et al., ADEPT: a computer program for prediction of protein antigenic determinants. Comput Appl Biosci. Jun. 1993;9(3):291-7.
Marshall et al., Poster Abstract No. P213 on pp. 271 to 272 entitled "A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults" for the 16th International Pathogenic Neisseria Conference Jul. 7, 2008 in Rotterdam, The Netherlands, available at http://neisseria.org/ipnc/2008/Abstracts_poster_presentations_IPNC_2008.pdf (last visited Feb. 22, 2017).
Martin et al., Highly conserved Neisseria meningitidis surface protein confers protection against experimental Infection. J Exp Med. Apr. 7, 1997;185(7):1173-83.
Mascioni et al., Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem. Mar. 27, 2009;284(13):8738-46.
Masignani et al., Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870, 2003 J. Exper. Med. 197(6): 789-799.
Meister et al., Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine. Apr. 1995;13(6):581-91.
Metruccio et al., A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog. Dec. 2009;5(12):e1000710.
Michon et al., Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel). 2000;103:151-60.
Michon et al.,Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine. Nov. 1998;16(18):1732-41.
Oriente et al., Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol. Feb. 2010;192(3):691-701.
Pajon et al., Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. Feb. 25, 2010;28(9):2122-9.
Panatto et al., Neisseria meningitidis B vaccines, 2011 Expert Rev. Vaccines 10(9): 1337-1351.
Perkins-Balding et al., Identification of functionally important regions of a haemoglobin receptor from Neisseria meningitidis. Microbiology. Dec. 2003;149(Pt 12):3423-35.
Porro et al., Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen. Mol Immunol. Aug. 1985;22(8):907-19.
Raddrizzani et al., Epitope scanning using virtual matrix-based algorithms. Brief Bioinform. May 2000;1(2):179-89.
Raghava and Barton, Quantification of the variation in percentage identity for protein sequence alignments, 2006 BMC Bioinformatics 7:415, 4 pages.
Ram et al., Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem. Dec. 19, 2003;278(51):50853-62.
Richmond et al., Poster Abstract No. P212 on pp. 270 to 271 entitled "A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years" for the 16th International Pathogenic Neisseria Conference Jul. 7, 2008 in Rotterdam, The Netherlands, available at http://neisseria.org/ipnc/2008/Abstracts_poster_presentations_IPNC_2008.pdf (last visited Feb. 22, 2017).
Roberts et al., Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res Hum Retroviruses. May 1, 1996;12(7):593-610.
Ruan et al., Protein D of Haemophilus influenzae. A novel bacterial surface protein with affinity for human IgD. J Immunol. Nov. 15, 1990;145(10):3379-84.
Rubinstein et al., Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity. J Immunol. Dec. 15, 1988;141(12):4357-62.
Rudinger J. In: Peptide Hormones. (Ed) JA Parsons, University Park Press, pp. 1-7, 1976. *
Santos et al., Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. May 2001;8(3):616-23.
Scarselli et al., Rational design of a meningococcal antigen inducing broad protective immunity, 2011 Sci. Transl. Med. 3(91): 91ra62; 12 total pages.
Schirle et al., Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Methods. Nov. 1, 2001;257(1-2):1-16.
Seid et al., Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability to Bind fH, To Mediate Serum Resistance, and to Induce Bactericidal Antibodies, 2011 Inf. & Immun. 79(2):970-981.
Skolnick et al. Trends in Biotechnology 18: 34-39, 2000. *
Tettelin et al., Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. Mar. 10, 2000;287(5459):1809-15.
Tong et al., Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform. Mar. 2007;8(2):96-108.
Tsurui et al., Prediction of T-cell epitope. J Pharmacol Sci. Dec. 2007;105(4):299-316.
Wang and Frasch, Development of a Neisseria meningitides Group B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model, 1984 Infection and Immunity 46(2): 408-414.
Welling et al., Prediction of sequential antigenic regions in proteins. FEBS Lett. Sep. 2, 1985;188(2):215-8.
Welsch et al., Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol. May 1, 2004;172(9):5606-15.
World Health Organization, WHO Expert Committee on Biological Standardization Fifty-fourth report, Annex 2 in the WHO Technical Report Series No. 927 at pp. 64-98, Geneva 2005, 35 total pages.
Zhu et al., Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun. Oct. 2005;73(10):6838-45.

Also Published As

Publication number Publication date
AU2011384634A1 (en) 2014-06-19
JP2015505309A (ja) 2015-02-19
WO2013098589A1 (en) 2013-07-04
BR112014016223A8 (pt) 2017-07-04
CA2862247A1 (en) 2013-07-04
EP2797624A1 (en) 2014-11-05
BR112014016223A2 (pt) 2017-06-13
US20150209419A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
US10568953B2 (en) Adjuvanting meningococcal factor H binding protein
US10596246B2 (en) Adjuvanted combinations of meningococcal factor H binding proteins
US10478483B2 (en) Combinations of meningococcal factor H binding proteins
AU2010227220B2 (en) Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
US20100189737A1 (en) Meningococcal vaccines including hemoglobin receptor
AU2014268243B2 (en) Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
AU2013202290A1 (en) Adjuvanting meningococcal factor H binding protein

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL, ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARICO, MARIA;BRUNELLI, BRUNELLA;COMANDUCCI, MAURIZIO;AND OTHERS;SIGNING DATES FROM 20140508 TO 20140606;REEL/FRAME:039082/0014

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:039082/0108

Effective date: 20160615

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:039082/0085

Effective date: 20140606

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4